Clot-busting drugs don't benefit older heart attack patients

Contrary to general belief among doctors, clot-busting drugs-- the main emergency treatment for heart attack victims --fail to benefit patients more than 75 years old and may actually increase their risk of death, according to results of a Johns Hopkins-led study.

Older heart attack patients who received intravenous thrombolytics, medications that dissolve clots in the blood vessels supplying the heart, were nearly 40 percent more likely to die within 30 days of treatment than their counterparts not given the medications, according to the study. Results are published in the May 16 issue of Circulation, an American Heart Association journal.

"There has been a widespread belief that clot-busting drugs help older patients just as they do younger ones, but the evidence always has been equivocal and the question had never been directly tested until now," says David R. Thiemann, M.D., lead author of the study and assistant professor of medicine at Hopkins. "We found that in actual clinical practice the effectiveness of these drugs varies markedly with age. Younger patients clearly benefit from thrombolytics, but the one-third of heart attack patients who are older than 75 are unlikely to have any benefit and may be at higher risk of death. More studies on how to treat the older population are urgently needed."

The study used data from the Cooperative Cardiovascular Project (conducted by the Health Care Financing Administration) on 7,864 Medicare patients aged 65 to 86, who arrived at hospitals with an acute heart attack and who were candidates for clot-dissolving therapy. There were 5,191 patients aged 65 to 75 and 2,673 patients aged 76 to 86.

Patients aged 65 to 75 who received thrombolytic therapy had a 30-day death rate of 6.8 percent, compared with 9.8 percent for patients who did not get the medications. Among patients aged 76 to 86 years, the pattern was reversed: The death rate for patients treated with thrombolytics was 18 perce

Contact: Karen Infeld
Johns Hopkins Medical Institutions

Page: 1 2

Related biology news :

1. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
2. New and better drugs for tuberculosis goal of UH professor
3. New technique helps scientists reveal interactions between genes and drugs
4. New database to help develop AIDS drugs
5. Orange, tangerine peels could be better than drugs for lowering cholesterol
6. New papillomavirus target could lead to specific antiviral drugs for precancerous cervical lesions
7. Newer drugs more effective at curing strep throat than penicillin
8. New software developed at Rensselaer predicts promising ingredients for new drugs
9. Protein abundant in human tumors confers resistance to anticancer drugs
10. Findings could aid efforts to harness nature for making drugs
11. New way to lock DNA-slicing enzyme onto chromosomes could lead to novel anti-cancer drugs

Post Your Comments:

(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/28/2020)... Fla. (PRWEB) , ... June 25, 2020 , ... In ... focus on innovations in accelerated Point of Care Testing solutions (POCT). Check local listings ... Samples are collected at medical offices and are shipped to labs throughout the country. ...
(Date:6/23/2020)... Md. (PRWEB) , ... June ... ... leading provider of gene-to-protein and monoclonal antibody development services, today announced that ... protein-based products and services to the pharmaceutical, diagnostics, and research industries. The ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis ... environments, announced today that Derek Fournier has been appointed CEO and President. Founder ... Board, effective immediately. , “DeCurtis Corporation has been on an incredible journey ...
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis Therapeutics, ... that it has filed an Investigational New Drug application (IND) with the U.S. ... its lead drug candidate NBTX-001 in patients with panic disorder (PD). , "Adding ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... I of a Small Business Innovation Research (SBIR) program funded by the National ... Rapid Toxin Detection in the Field”. The project’s goal was to engineer and ...
(Date:6/3/2020)... ... June 03, 2020 , ... ... applications of biofeedback. In the next installment, Dr. Inna Khazan will discuss the ... learn to bring their attention to the feelings, thoughts, and emotions they are ...
Breaking Biology Technology:
Cached News: